vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and PLAYSTUDIOS, Inc. (MYPS). Click either name above to swap in a different company.
PLAYSTUDIOS, Inc. is the larger business by last-quarter revenue ($55.4M vs $44.9M, roughly 1.2× AbCellera Biologics Inc.). AbCellera Biologics Inc. runs the higher net margin — -19.9% vs -24.7%, a 4.8% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs -18.3%). PLAYSTUDIOS, Inc. produced more free cash flow last quarter ($3.6M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs -15.6%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
ABCL vs MYPS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $55.4M |
| Net Profit | $-8.9M | $-13.7M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | -17.7% |
| Net Margin | -19.9% | -24.7% |
| Revenue YoY | 788.4% | -18.3% |
| Net Profit YoY | 73.9% | 38.9% |
| EPS (diluted) | $-0.03 | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $55.4M | ||
| Q3 25 | $9.0M | $57.6M | ||
| Q2 25 | $17.1M | $59.3M | ||
| Q1 25 | $4.2M | $62.7M | ||
| Q4 24 | $5.0M | $67.8M | ||
| Q3 24 | $6.5M | $71.2M | ||
| Q2 24 | $7.3M | $72.6M | ||
| Q1 24 | $10.0M | $77.8M |
| Q4 25 | $-8.9M | $-13.7M | ||
| Q3 25 | $-57.1M | $-9.1M | ||
| Q2 25 | $-34.7M | $-2.9M | ||
| Q1 25 | $-45.6M | $-2.9M | ||
| Q4 24 | — | $-22.4M | ||
| Q3 24 | $-51.1M | $-3.1M | ||
| Q2 24 | $-36.9M | $-2.6M | ||
| Q1 24 | $-40.6M | $-567.0K |
| Q4 25 | -63.7% | -17.7% | ||
| Q3 25 | -851.8% | -13.6% | ||
| Q2 25 | -290.2% | -5.9% | ||
| Q1 25 | -1479.6% | -4.4% | ||
| Q4 24 | — | -33.1% | ||
| Q3 24 | -1439.4% | -6.7% | ||
| Q2 24 | -1276.2% | -5.5% | ||
| Q1 24 | -551.5% | -2.2% |
| Q4 25 | -19.9% | -24.7% | ||
| Q3 25 | -637.8% | -15.8% | ||
| Q2 25 | -203.3% | -5.0% | ||
| Q1 25 | -1077.2% | -4.6% | ||
| Q4 24 | — | -33.1% | ||
| Q3 24 | -785.4% | -4.3% | ||
| Q2 24 | -504.3% | -3.6% | ||
| Q1 24 | -408.0% | -0.7% |
| Q4 25 | $-0.03 | $-0.12 | ||
| Q3 25 | $-0.19 | $-0.07 | ||
| Q2 25 | $-0.12 | $-0.02 | ||
| Q1 25 | $-0.15 | $-0.02 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | $-0.17 | $-0.02 | ||
| Q2 24 | $-0.13 | $-0.02 | ||
| Q1 24 | $-0.14 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $104.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $227.9M |
| Total Assets | $1.4B | $290.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | $104.9M | ||
| Q3 25 | $83.2M | $106.3M | ||
| Q2 25 | $92.4M | $112.9M | ||
| Q1 25 | $159.3M | $107.1M | ||
| Q4 24 | $156.3M | $109.2M | ||
| Q3 24 | $126.6M | $105.2M | ||
| Q2 24 | $148.3M | $106.3M | ||
| Q1 24 | $123.6M | $127.0M |
| Q4 25 | $966.9M | $227.9M | ||
| Q3 25 | $964.0M | $238.9M | ||
| Q2 25 | $1.0B | $245.3M | ||
| Q1 25 | $1.0B | $244.1M | ||
| Q4 24 | $1.1B | $244.7M | ||
| Q3 24 | $1.1B | $265.2M | ||
| Q2 24 | $1.1B | $263.6M | ||
| Q1 24 | $1.1B | $288.4M |
| Q4 25 | $1.4B | $290.6M | ||
| Q3 25 | $1.4B | $299.2M | ||
| Q2 25 | $1.4B | $316.2M | ||
| Q1 25 | $1.3B | $313.8M | ||
| Q4 24 | $1.4B | $323.0M | ||
| Q3 24 | $1.4B | $330.6M | ||
| Q2 24 | $1.4B | $333.4M | ||
| Q1 24 | $1.5B | $357.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $3.7M |
| Free Cash FlowOCF − Capex | $-44.6M | $3.6M |
| FCF MarginFCF / Revenue | -99.4% | 6.5% |
| Capex IntensityCapex / Revenue | 21.9% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $25.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $3.7M | ||
| Q3 25 | $-52.6M | $5.7M | ||
| Q2 25 | $-32.4M | $13.6M | ||
| Q1 25 | $-11.6M | $3.3M | ||
| Q4 24 | $-108.6M | $11.6M | ||
| Q3 24 | $-28.9M | $14.6M | ||
| Q2 24 | $-30.0M | $14.5M | ||
| Q1 24 | $-41.7M | $5.0M |
| Q4 25 | $-44.6M | $3.6M | ||
| Q3 25 | $-61.5M | $5.4M | ||
| Q2 25 | $-45.8M | $13.2M | ||
| Q1 25 | $-22.2M | $3.2M | ||
| Q4 24 | $-187.0M | $11.5M | ||
| Q3 24 | $-47.4M | $13.9M | ||
| Q2 24 | $-50.1M | $12.8M | ||
| Q1 24 | $-65.8M | $3.6M |
| Q4 25 | -99.4% | 6.5% | ||
| Q3 25 | -687.0% | 9.3% | ||
| Q2 25 | -267.9% | 22.3% | ||
| Q1 25 | -524.0% | 5.1% | ||
| Q4 24 | -3702.8% | 16.9% | ||
| Q3 24 | -728.4% | 19.6% | ||
| Q2 24 | -683.8% | 17.6% | ||
| Q1 24 | -661.5% | 4.6% |
| Q4 25 | 21.9% | 0.2% | ||
| Q3 25 | 99.7% | 0.5% | ||
| Q2 25 | 78.2% | 0.7% | ||
| Q1 25 | 251.1% | 0.2% | ||
| Q4 24 | 1552.7% | 0.2% | ||
| Q3 24 | 284.6% | 0.9% | ||
| Q2 24 | 274.6% | 2.4% | ||
| Q1 24 | 242.5% | 1.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
